Spirogen develops antibody-drug conjugate technology, which can directly target tumors while protecting healthy cells.
AstraZeneca will pay $200M up front and $240M in milestones.
The drugs giant will also buy a stake in ADC Therapeutics, which has a licensing agreement with Spirogen, for $20M.
AstraZeneca's shares are +0.5% in London. (PR)